公开(公告)号：US20230002400A1

公开(公告)日：2023-01-05

申请号：US17779197

申请日：2020-11-27

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xinye YANG ,  Liang CHEN ,  Yuefeng SHAN ,  Xiaojun WANG

IPC: C07D491/044

Abstract: An amorphous form of a nitrogen-containing tricyclic compound and a use thereof, a pharmaceutical composition containing the compound in the amorphous form, and the use of the compound in the amorphous form or the pharmaceutical composition in the preparation of a drug for preventing, treating or alleviating FXR-mediated diseases in a patient.

公开(公告)号：US20230002351A1

公开(公告)日：2023-01-05

申请号：US16639051

申请日：2018-08-13

Applicant: GLOBAL BLOOD THERAPEUTICS, INC.

Inventor： ZHE LI ,  MING YU ,  QING XU ,  MANUEL ZANCANELLA

IPC: C07D401/12 ,  C07D215/42 ,  C07D401/14 ,  C07D405/14 ,  C07D491/056 ,  C07D491/044 ,  C07B59/00 ,  C07D487/04 ,  C07D413/12 ,  C07D453/02 ,  C07D487/08

Abstract: The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

公开(公告)号：US20220024861A1

公开(公告)日：2022-01-27

申请号：US17489654

申请日：2021-09-29

Applicant: ORIENTAL(LUZHOU) AGROCHEMICALS CO., LTD.

Inventor： Bangchi CHEN ,  Yinwei SUN ,  Zhongyuan WANG ,  Teng LAI

IPC: C07C255/31 ,  C07C253/30 ,  C07D491/044 ,  C07C231/06

Abstract: Disclosed are a type of conjugated triene compounds (1), and a preparation and application thereof. In this method, a 2-(cyclohexenylidene)malonic acid derivative is sequentially subjected to isomerization, halogenation reaction in the presence of a halogenating agent and dehydrohalogenation to prepare the conjugated triene compounds (1). This disclosure further provides a method of preparing a 2-aryl malonic acid derivative from the conjugated triene compounds (1) through aromatization reaction.

公开(公告)号：US11066413B2

公开(公告)日：2021-07-20

申请号：US16491459

申请日：2018-03-07

Applicant: GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

Inventor： Yuguang Wang ,  Nong Zhang ,  Tianzhi Wu

IPC: C07D491/044 ,  C07D473/00 ,  C07D487/04 ,  A61K31/519

Abstract: Disclosed in the present invention is an aminopyrimidine five-membered heterocyclic compound, and an intermediate, preparation method, pharmaceutical composition and application thereof. The aminopyrimidine five-membered heterocyclic compound provided by the present invention has a significant antagonistic effect on adenosine A2A receptors, and may be used as an antagonist for adenosine A2A receptors to effectively relieve or treat immune tolerance, diseases of the central nervous system, inflammatory diseases and like related diseases, while the preparation method is simple.

公开(公告)号：US10981926B2

公开(公告)日：2021-04-20

申请号：US16677906

申请日：2019-11-08

Applicant: Janssen Pharmaceutica NV

Inventor： Gilles Bignan ,  Peter J. Connolly ,  Ian Hickson ,  Lieven Meerpoel ,  Vineet Pande ,  Zhuming Zhang ,  Jonathan Branch ,  Christian Rocaboy ,  Luis B. Trabalón Escolar

IPC: C07D491/10 ,  C07D491/107 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D409/14 ,  C07D451/02 ,  C07D451/06 ,  C07D487/04 ,  C07D491/044 ,  C07D491/048 ,  A61K9/00 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/573 ,  A61K31/58

Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.

公开(公告)号：US20210047339A1

公开(公告)日：2021-02-18

申请号：US16992961

申请日：2020-08-13

Applicant: ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.

Inventor： Zhiguo ZHENG

IPC: C07D491/044

Abstract: The present invention relates to a method for preparing Asenapine. In particular, the present invention relates to a method for preparing pharmaceutically acceptable Asenapine free base and new crystal form thereof, and also relates to methods for preparing the intermediate compounds used in said method.

公开(公告)号：US10562910B2

公开(公告)日：2020-02-18

申请号：US16322945

申请日：2017-08-02

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xiaojun Wang ,  Xinye Yang ,  Junwen Wu ,  Shaohui Xiong ,  Shengqiang Pan ,  Shengtian Cao ,  Yingjun Zhang

IPC: C07D491/044 ,  C07D491/056 ,  A61K31/4164 ,  A61P9/04 ,  A61K31/4353 ,  A61P15/00 ,  A61P5/50 ,  A61P9/12 ,  A61P7/02 ,  A61P9/10 ,  A61K31/42 ,  C07D491/107

Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

公开(公告)号：US20190280218A1

公开(公告)日：2019-09-12

申请号：US16419095

申请日：2019-05-22

Applicant: AMIR HOSSAIN PARHAM ,  Arne Buesing ,  Philipp Stoessel ,  Anja Gerhard ,  Christof Pflumm ,  Thomas Eberle ,  Anja Jatsch ,  Jonas Valentin Kroeber ,  Lars Dobelmann-Mara

Inventor： AMIR HOSSAIN PARHAM ,  Arne Buesing ,  Philipp Stoessel ,  Anja Gerhard ,  Christof Pflumm ,  Thomas Eberle ,  Anja Jatsch ,  Jonas Valentin Kroeber ,  Lars Dobelmann-Mara

IPC: H01L51/00 ,  C07D405/10 ,  C07D313/06 ,  A61N5/06 ,  C07D405/04 ,  C07D405/14 ,  C07D407/04 ,  C07D407/10 ,  C07D407/12 ,  C07D407/14 ,  C07D487/04 ,  C09K11/06 ,  C09K11/02 ,  C07D491/044

Abstract: The invention relates to materials, to electroluminescence devices comprising said materials and to the use thereof.

公开(公告)号：US20180362542A1

公开(公告)日：2018-12-20

申请号：US16062680

申请日：2016-12-14

Applicant: Novartis AG

Inventor： Robert John AVERSA ,  Matthew T. BURGER ,  Michael Patrick DILLON ,  Thomas A. DINEEN, Jr. ,  Rajesh KARKI ,  Savrithi RAMURTHY ,  Vivek RAUNIYAR ,  Richard ROBINSON ,  Patrick James SARVER

IPC: C07D498/04 ,  C07D491/044 ,  C07D487/04 ,  A61P35/00

CPC classification number: C07D498/04 ,  A61P35/00 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044

Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.

公开(公告)号：US20180346484A1

公开(公告)日：2018-12-06

申请号：US15882008

申请日：2018-01-29

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Irini Akritopoulou-Zanze ,  Wilfried Braje ,  Stevan W. Djuric ,  Noel S. Wilson ,  Sean C. Turner ,  Albert W. Kruger ,  Ana-Lucia Relo ,  Shashank Shekhar ,  Dennie S. Welch ,  Hongyu Zhao ,  Jorge Gandarilla ,  Alan F. Gasiecki ,  Huanqiu Li ,  Christina M. Thompson ,  Min Zhang

IPC: C07D513/04 ,  C07D495/16 ,  C07D487/04 ,  C07D495/04 ,  C07D491/04 ,  C07D491/044

CPC classification number: C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044 ,  C07D495/04 ,  C07D495/16

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.